Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.35 USD

77.35
3,319,830

+0.48 (0.62%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (66 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

    Arpita Dutt headshot

    Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

    Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

      Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

      Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

        J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

        Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.

          AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

          AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

            Intellipharmaceutics Announces Launch of Generic Seroquel XR

            Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company

              Incyte Provides Updated Data on Cancer Combination Therapies

              Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.

                Incyte Announces Data on Enzyme Inhibitor with Keytruda

                Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.

                  Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

                  Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

                    Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

                    On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

                      Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                      After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                        AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk

                        AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.

                          The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac

                          The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac

                            AstraZeneca Sells Marketing Rights to Seloken in Europe

                            AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.

                              AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions

                              AstraZeneca (AZN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

                                Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

                                Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

                                  Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

                                  On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

                                    Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

                                    We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

                                      AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

                                      AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

                                        AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

                                        AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

                                          What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                          Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

                                            While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

                                              Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1

                                              Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.

                                                Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss

                                                Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

                                                  Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.